A Practical Primer for M&A Deal Lawyers

One missing consent can turn a $500 million closing into a midnight hostage negotiation. In this overview episode, we read a representative private-company SPA the way deal lawyers actually use it: as an interlocking risk-allocation system, not a stack of isolated clauses. The conversation tracks how deal structure changes the wrapper across SPAs, APAs, MIPAs, and merger agreements; how Article 1 and Article 2 definitions drive price through working capital, debt, true-up, and locked-box mechanics; and how the Article 3 to Article 6 to Article 7 pipeline converts diligence into closing leverage or post-closing exposure. It also covers RWI limits, regulatory gap risk, disclosure schedules, and why closing deliverables carry real economic consequences.

One missing consent can turn a signed deal into an enforceability fight. In this episode, we dig into authority failures that surface when teams assume title, practical control, or parent ownership is enough to bind an entity. The discussion distinguishes signer authority from entity authorization, walks through why LLC, corporation, and LP approval mechanics are not interchangeable, and shows how operating agreements, side letters, and subsidiary-chain gaps create hidden closing risk. It also covers what a fourth-year should actually do on the authority workstream, why secretary certificates are evidence rather than cure-alls, and how broken authority analysis can cascade into reps, closing conditions, RWI exclusions, lender pushback, and post-closing leverage.

A two-page LOI can decide who bleeds at midnight. This episode treats the front end of private M&A as the place where leverage, structure, and downstream drafting pain are set. The discussion covers NDAs and process letters as control documents, why "non-binding" LOIs still shape real outcomes, and how exclusivity should be priced and milestoned rather than handed out. It then turns to structure selection: stock sale, asset sale, merger, and triangular variants, as a risk-allocation choice that changes consent analysis, liability exposure, tax modeling, and the entire closing stack. The episode also walks through first-draft advantage, Meso Scale consent traps in reverse triangular mergers, and why early tax calls can create or eliminate leverage months before signing.

A buried row in the diligence tracker can move millions of dollars into escrow. This episode treats diligence as a decision system, not a document-review exercise, and follows how buyer-side findings become actual deal action in private M&A. The conversation covers the associate workflow from DDRL launch through uneven data-room production and follow-up Q&A; the difference between a tracker, issue list, internal memo, and client-facing red-flags report; what makes an escalation useful; and why diligence materiality is a judgment tool rather than a mirror of contract drafting. Using a customer contract with a change-of-control termination right, the episode traces one finding through reps, schedules, covenants, closing conditions, specific indemnity, escrow, and RWI exclusion.

A $286 million headline can still leave only about $220 million hitting the wire. This episode examines how deal lawyers translate valuation stories into contractual price mechanics, and why enterprise value, finance-side equity value, contractual equity value, and seller proceeds are four different numbers. The conversation walks through the enterprise-to-equity bridge with cash, debt, transaction expenses, and working-capital adjustments; challenges aggressive adjusted EBITDA add-backs and double counting; compares a noisy true-up structure against a cleaner fixed-price bid; and explains why rollover equity, leakage protection, and tax-structure sensitivity can change the real economics without changing the headline price.

A $4 million swing can sit inside a single working-capital definition. This episode examines how a closing-accounts true-up becomes a negotiation over price, seasonality, and post-closing leverage in a $150 million deal for a seasonal distribution business. The conversation pits a trailing-twelve-month peg against a last-month-end peg, then digs into the accounting hierarchy among GAAP, past practice, deal-specific methodologies, and the sample balance sheet that makes commercial intent executable. It also covers the consistency-versus-correctness trap, collars and de minimis thresholds, buyer control of the closing statement, true-up payment security when the escrow is short, and why customer advances, banker fees, and covenant claims do not all belong in the same dispute lane.

A $15 million earnout can evaporate even when the product is performing. This episode examines how contingent consideration shifts risk after closing in a founder sale of a cybersecurity SaaS company to a PE buyer planning immediate integration. The conversation breaks the earnout into four bargains — price, operating behavior, measurement, and payment security — and shows how metric choice between ARR, revenue, EBITDA, and bookings creates different manipulation risks. It also covers bundling and attribution rules, dedicated-sales-team and anti-diversion covenants, the Delaware implied-covenant backdrop for earnout fights, accounting hierarchy and deferred-revenue distortions, change-of-control acceleration, credit support, and the point at which an earnout is so synthetic that rollover equity, retention arrangements, or no earnout may be the cleaner answer.

A single qualifier can turn a core rep into a cosmetic promise. This episode examines which SPA representations actually drive claims and leverage in private M&A, and why the loudest markup fights often miss the real risk. The conversation breaks down statement architecture through scope, qualifiers, timing, and remedial consequence; the distinction between fundamental and general reps in setting survival, caps, and baskets; how materiality, MAE, and knowledge qualifiers reprice what the seller is actually promising; and why sandbagging, schedule design, bringdown mechanics, and late schedule updates determine whether a rep works at signing, at closing, or only on paper. It also covers overlooked interim-operating, full-disclosure, buyer, and emerging AI-specific reps.

At 2 a.m., a vague schedule entry can erase the protection a heavily negotiated rep was supposed to deliver. This episode treats disclosure schedules as the deal’s routing layer: the mechanism that decides whether a fact actually qualifies a rep, forces a rewrite, supports a special indemnity, or should change price. Using a late-night schedule review triage, the conversation walks through unusable material-contract and litigation entries, why "see data room folder 4.3.2" usually is not contractual disclosure, how contradictory scheduled facts must be analyzed against the rep text and disclosure legend, and why portability, fair-disclosure standards, double materiality, and post-signing supplements reshape buyer leverage and RWI outcomes. It also flags AI contract schedules as a growing drafting pressure point.

A bracketed scrape clause can decide whether a six-figure problem ever reaches the indemnity ledger. This debate episode tests full-scrape and selective-scrape positions against the rest of the SPA architecture rather than treating the clause in isolation. The discussion works through breach versus loss-calculation scrapes, deductible versus tipping baskets, the double-materiality trap created by rep text and schedule filtering, and the sandbagging collision when a buyer knew about the issue before closing. It also covers mini-baskets, subject-defining materiality in reps like material contracts, and why RWI underwriters may see a full scrape as either cleaner claims mechanics or added operational noise.

A decision that saves the business can still hand the buyer a closing weapon. This episode treats the ordinary-course covenant as the interim governance charter for a company with two masters, then runs three live-fire scenarios through the text: a 15% concession for a 22%-of-revenue customer, $800,000 in retention bonuses blocked by a no-increase-in-compensation covenant, and $1.2 million of emergency repairs against a $500,000 capex limit. The discussion tracks AB Stable’s pressure on "consistent with past practice," why consent mechanics and response timing are substance rather than process, how efforts standards allocate execution burden, and why operating matrices, gun-jumping discipline, and emergency carveouts now sit at the center of interim-covenant drafting.

Two weeks from the outside date, a 28% revenue drop can turn a signed SPA into trench warfare. This episode stages a live buyer-seller showdown over whether a $300 million private deal still has to close after customer losses, a new regulatory investigation, a CFO resignation, and a nervous lender. The discussion works through why MAE is a risk-allocation concept rather than shorthand for business disappointment, how Akorn and durational significance shape the analysis, and why bringdown wording, officer certificates, and ordinary-course compliance can matter more than headline deterioration. It also covers specific performance under IBP v. Tyson, reverse termination fees, financing failure, and the leverage created by waiver, cure, and outside-date mechanics.

At 1 a.m., six words in the MAE definition can move nine figures of sign-to-close risk. This episode is a technical markup drill on the private-company MAE clause itself, starting with the forward-looking prong, the aggregation language, and the buyer's attempt to build a mosaic while the seller tries to atomize the facts. It then works clause by clause through the carveouts for macro conditions, industry shifts, law and GAAP changes, pandemics, force-majeure-style events, war, announcement effects, and buyer-caused consequences, before turning to disproportionate-effects pullbacks, comparator fights, and the meaning of company and subsidiaries taken as a whole. The episode ends by tracing where the definition actually bites in MAE-qualified reps, bringdown conditions, standalone no-MAE closings, and interim-covenant disputes.

Eight months after closing, one unscheduled change-of-control clause turns a $4 million customer loss into a live test of whether the SPA's remedies architecture actually works. Using an undisclosed termination right in the target's largest customer contract, this episode treats indemnification as a negotiated recovery system rather than a boilerplate afterthought. It walks through notice timing and specificity, lane classification across rep breach, covenant breach, schedule deficiency, and fraud theories, the economics of a $500K tipping basket versus a true deductible, and the interaction of survival periods, caps, the definition of Losses, escrow collectability, sandbagging, exclusive-remedy clauses, and the RWI layer. The result is a practical claims map for lawyers who draft these provisions under signing pressure.

A $3.5 million contract loss is where the promise of a clean exit starts to break down. This episode takes the undisclosed change-of-control termination-right claim from Episode 13 and runs it through the RWI layer, focusing on buy-side policy structure, the underwriting record, and the line between an unknown breach and a known issue. It covers no-known-loss and no-known-circumstances declarations, retention mechanics that may look very different from the SPA basket, notice and proof requirements, and the subrogation limits that usually matter most to sellers. The discussion also shows why policy wording, knowledge imputation, and fraud carveout alignment across the SPA and policy can decide whether insurance is real recourse or just optics.

$30 million of hidden IP exposure is where boilerplate stops being boilerplate. This episode stages a buyer-seller debate over a patent claim allegedly concealed by the seller's CEO and uses that fight to test the real boundary between extra-contractual fraud and lies embedded in the reps themselves. It works through FdG Logistics, ABRY Partners, and Prairie Capital, then turns to the drafting choices that decide who can actually be sued: fraud definitions, carveout scope, survival periods, exclusive-remedy language, and non-recourse provisions. The second half shifts to broken-deal remedies, including must-close, efforts-plus-fee, and hybrid models, plus specific performance, reverse termination fees, willful-breach language, and the sponsor guarantee chain.

A $20 million headline bump can disappear the moment you trace the recourse. This episode puts a $420 million sponsor bid next to a $400 million strategic offer and asks what the board is really being paid for. The discussion breaks down debt commitment letters, highly confident letters, SunGard-style certain-funds mechanics, market flex, and the side-door financing risk hidden in marketing-period covenants. It then turns to the equity commitment cap, reverse termination fee sizing, and the conditional nature of specific performance in financed deals. The second half focuses on management rollover as a new investment with conflict, governance, drag-along and tag-along implications, plus why RWI often produces exclusions, special escrows, or both.

When a buyer wants out, sloppy case lore is expensive. This episode revisits the Delaware decisions that actually changed private M&A drafting and strips away the slogans lawyers repeat in markups. The discussion works through IBP v. Tyson on specific performance, Akorn on what an MAE record had to look like, AB Stable on ordinary-course covenants tied to past practice, and ABRY Partners on the line between extra-contractual anti-reliance and lies inside the reps. It then treats Snow Phipps more carefully, focusing on financing-efforts obligations, prevention-doctrine pressure, and why reverse-termination-fee exclusivity depends on the remedies stack and breach theory. The episode closes by isolating the provisions that most often decide the fight: reliance architecture, ordinary-course language, specific-performance triggers, efforts covenants, and fee exclusivity.

The clean closing myth dies fast once a live deal starts moving. This capstone episode walks through a $200 million healthcare-services acquisition from kickoff call to month-eight claim, showing how authority, structure, conflicts, LOI leverage, and diligence findings become drafting choices in the SPA. It covers how a pending regulatory inquiry and a related-party lease migrate into price, covenants, schedules, and a special indemnity; why the real negotiation fights sit in the working capital peg, materiality scrape, sandbagging, RWI, and earnout mechanics; and how HSR delay, ordinary-course covenants, MAE posturing, bringdown certificates, funds flow, and payoff-letter choreography decide whether the wires actually move. The episode closes by tracing a later enforcement action through baskets, caps, exclusions, and the fraud question.

A $300 million AI target can turn into a paperweight if the model was trained on data the company never had the right to use. This deep dive gives deal lawyers a spotting-and-routing framework for AI risk across three postures: buying an AI company, buying a business that uses third-party AI, and buying a vendor or contractor selling or operating AI workflows for customers. The discussion covers training-data provenance, ownership of models, weights, outputs, open-source dependencies, bias and compliance reps, interim covenants around deployment changes, the agentic-AI contract checklist for vendor and customer paper, downstream liability allocation, and the still-forming RWI response to known AI issues. It also maps when pricing, earnouts, retention, escrows, or structure may need to move.